设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 433|回复: 0

间皮质靶向CAR-T细胞局部注射治疗具有潜在和长期的CD4依赖性肿瘤免疫效应。

[复制链接]
发表于 2015-12-3 22:41:07 | 显示全部楼层 |阅读模式
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Abstract
Translating the recent success of chimeric antigen receptor (CAR) T cell therapy for hematological malignancies to solid tumors will necessitate overcoming several obstacles, including inefficient T cell tumor infiltration and insufficient functional persistence. Taking advantage of an orthotopic model that faithfully mimics human pleural malignancy, we evaluated two routes of administration of mesothelin-targeted T cells using the M28z CAR. We found that intra-pleurally administered CAR T cells vastly out-performed systemically infused T cells, requiring 30-fold fewer M28z T cells to induce long-term complete remissions. Following intrapleural T cell administration, prompt in vivo antigen-induced T cell activation allowed robust CAR T cell expansion and effector differentiation, resulting in enhanced anti-tumor efficacy and functional T cell persistence for 200 days. Regional T cell administration also promoted efficient elimination of extrathoracic tumor sites. This therapeutic efficacy was dependent on early CD4+ T cell activation associated with a higher intra-tumoral CD4/CD8 cell ratios and CD28-dependent CD4+ T cell-mediated cytotoxicity. In contrast, intravenously delivered CAR T cells, even when accumulated at equivalent numbers in the pleural tumor, did not achieve comparable activation, tumor eradication or persistence. The remarkable ability of intrapleurally administered T cells to circulate and persist supports the concept of delivering optimal CAR T cell therapy through “regional distribution centers.” Based on these results, we are opening a phase I clinical trial to evaluate the safety of intrapleural administration of mesothelin-targeted CAR T cells in patients with primary or secondary pleural malignancies.
间皮质靶向CAR-T细胞局部注射治疗具有潜在和长期的CD4依赖性肿瘤免疫效应
摘要:
CAR-T细胞移植治疗恶性血液系统肿瘤获得成功,若要转到实体肿瘤的治疗必须克服几个障碍,包括低效率的T细胞对肿瘤的浸润以及功能持久性不足。利用一个原位模型准确的模仿胸膜恶性肿瘤,我们评估了使用M28z CAR的间皮质靶向CAR-T细胞的两种给药途径。我们发现,向胸膜内注射CAR-T细胞大大优于全身注射CAR-T细胞,可以需要少30的m28z T细胞来诱导长期完全的缓解。在胸腔内注射T细胞之后,在体内抗原诱导的T 细胞迅速活化,CAR-T细胞扩增并且功能性分化,产生了抗肿瘤活性并能持续200天。T细胞局部注射也促进了胸外肿瘤有效的消除。这个治疗的有效性取决于早期CD4+T细胞活化,与较高的肿瘤内CD4CD8细胞比例和CD28依赖的CD4 + T细胞介导的细胞毒作用有关。相反的,静脉注射的CAR-T细胞,即使在胸腔肿瘤积累相同的数量,也没有起到相对应的活性、肿瘤根除或持久性。胸腔内注射T细胞的有效性支持了这么一个观点:通过区域性注射中心可以进行最优化的CAR-T细胞治疗。基于这些结果,我们正开放一个I期临床试验,评估原发或继发胸膜恶性肿瘤患者胸腔内注射间皮素靶向T细胞的安全性。
出自爱康得生物技术

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and.pdf

2.43 MB, 下载次数: 61

您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-3-2 01:46 , Processed in 0.104383 second(s), 27 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表